Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies

Antonio Brucato, Rolando Cimaz, Roberto Caporali, Véronique Ramoni, Jill Buyon

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Anti-Ro/SSA antibodies are associated with neonatal lupus (congenital heart block (CHB), neonatal transient skin rash, hematological and hepatic abnormalities), but do not negatively affects other gestational outcomes, and the general outcome of these pregnancies is now good, when followed by experienced multidisciplinary teams. The prevalence of CHB, defined as an atrioventricular block diagnosed in utero, at birth, or within the neonatal period (0-27 days after birth), in the offspring of an anti-Ro/SSA-positive women is 1-2%, of neonatal lupus rash around 10-20%, while laboratory abnormalities in asymptomatic babies can be detected in up to 27% of cases. The risk of recurrence of CHB is ten times higher. Most of the mothers are asymptomatic at delivery and are identified only by the birth of an affected child. Half of these asymptomatic women develop symptoms of a rheumatic disease, most commonly arthralgias and xerophtalmia, but few develop lupus nephritis. A standard therapy for CHB is still matter of investigation, although fluorinated corticosteroids have been reported to be effective for associated cardiomyopathy. Serial echocardiograms and obstetric sonograms, performed at least every 1-2 weeks starting from the 16th week of gestational age, are recommended in anti-Ro/SSA-positive pregnant women to detect early fetal abnormalities that might be a target of preventive therapy.

Original languageEnglish
Pages (from-to)27-41
Number of pages15
JournalClinical Reviews in Allergy and Immunology
Volume40
Issue number1
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Pregnancy Outcome
Autoimmune Diseases
Parturition
Exanthema
Lupus Nephritis
Atrioventricular Block
Arthralgia
Rheumatic Diseases
Cardiomyopathies
Gestational Age
Obstetrics
Pregnant Women
Adrenal Cortex Hormones
Mothers
Recurrence
Congenital heart block
SS-A antibodies
Liver
Therapeutics
Neonatal Systemic lupus erythematosus

Keywords

  • Anti-Ro/SSA antibodies
  • Heart block/congenital
  • Neonatal lupus

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. / Brucato, Antonio; Cimaz, Rolando; Caporali, Roberto; Ramoni, Véronique; Buyon, Jill.

In: Clinical Reviews in Allergy and Immunology, Vol. 40, No. 1, 02.2011, p. 27-41.

Research output: Contribution to journalArticle

@article{4e906c21f4bc44d1aa6ee52e23c4f5b3,
title = "Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies",
abstract = "Anti-Ro/SSA antibodies are associated with neonatal lupus (congenital heart block (CHB), neonatal transient skin rash, hematological and hepatic abnormalities), but do not negatively affects other gestational outcomes, and the general outcome of these pregnancies is now good, when followed by experienced multidisciplinary teams. The prevalence of CHB, defined as an atrioventricular block diagnosed in utero, at birth, or within the neonatal period (0-27 days after birth), in the offspring of an anti-Ro/SSA-positive women is 1-2{\%}, of neonatal lupus rash around 10-20{\%}, while laboratory abnormalities in asymptomatic babies can be detected in up to 27{\%} of cases. The risk of recurrence of CHB is ten times higher. Most of the mothers are asymptomatic at delivery and are identified only by the birth of an affected child. Half of these asymptomatic women develop symptoms of a rheumatic disease, most commonly arthralgias and xerophtalmia, but few develop lupus nephritis. A standard therapy for CHB is still matter of investigation, although fluorinated corticosteroids have been reported to be effective for associated cardiomyopathy. Serial echocardiograms and obstetric sonograms, performed at least every 1-2 weeks starting from the 16th week of gestational age, are recommended in anti-Ro/SSA-positive pregnant women to detect early fetal abnormalities that might be a target of preventive therapy.",
keywords = "Anti-Ro/SSA antibodies, Heart block/congenital, Neonatal lupus",
author = "Antonio Brucato and Rolando Cimaz and Roberto Caporali and V{\'e}ronique Ramoni and Jill Buyon",
year = "2011",
month = "2",
doi = "10.1007/s12016-009-8190-6",
language = "English",
volume = "40",
pages = "27--41",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies

AU - Brucato, Antonio

AU - Cimaz, Rolando

AU - Caporali, Roberto

AU - Ramoni, Véronique

AU - Buyon, Jill

PY - 2011/2

Y1 - 2011/2

N2 - Anti-Ro/SSA antibodies are associated with neonatal lupus (congenital heart block (CHB), neonatal transient skin rash, hematological and hepatic abnormalities), but do not negatively affects other gestational outcomes, and the general outcome of these pregnancies is now good, when followed by experienced multidisciplinary teams. The prevalence of CHB, defined as an atrioventricular block diagnosed in utero, at birth, or within the neonatal period (0-27 days after birth), in the offspring of an anti-Ro/SSA-positive women is 1-2%, of neonatal lupus rash around 10-20%, while laboratory abnormalities in asymptomatic babies can be detected in up to 27% of cases. The risk of recurrence of CHB is ten times higher. Most of the mothers are asymptomatic at delivery and are identified only by the birth of an affected child. Half of these asymptomatic women develop symptoms of a rheumatic disease, most commonly arthralgias and xerophtalmia, but few develop lupus nephritis. A standard therapy for CHB is still matter of investigation, although fluorinated corticosteroids have been reported to be effective for associated cardiomyopathy. Serial echocardiograms and obstetric sonograms, performed at least every 1-2 weeks starting from the 16th week of gestational age, are recommended in anti-Ro/SSA-positive pregnant women to detect early fetal abnormalities that might be a target of preventive therapy.

AB - Anti-Ro/SSA antibodies are associated with neonatal lupus (congenital heart block (CHB), neonatal transient skin rash, hematological and hepatic abnormalities), but do not negatively affects other gestational outcomes, and the general outcome of these pregnancies is now good, when followed by experienced multidisciplinary teams. The prevalence of CHB, defined as an atrioventricular block diagnosed in utero, at birth, or within the neonatal period (0-27 days after birth), in the offspring of an anti-Ro/SSA-positive women is 1-2%, of neonatal lupus rash around 10-20%, while laboratory abnormalities in asymptomatic babies can be detected in up to 27% of cases. The risk of recurrence of CHB is ten times higher. Most of the mothers are asymptomatic at delivery and are identified only by the birth of an affected child. Half of these asymptomatic women develop symptoms of a rheumatic disease, most commonly arthralgias and xerophtalmia, but few develop lupus nephritis. A standard therapy for CHB is still matter of investigation, although fluorinated corticosteroids have been reported to be effective for associated cardiomyopathy. Serial echocardiograms and obstetric sonograms, performed at least every 1-2 weeks starting from the 16th week of gestational age, are recommended in anti-Ro/SSA-positive pregnant women to detect early fetal abnormalities that might be a target of preventive therapy.

KW - Anti-Ro/SSA antibodies

KW - Heart block/congenital

KW - Neonatal lupus

UR - http://www.scopus.com/inward/record.url?scp=79951672892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951672892&partnerID=8YFLogxK

U2 - 10.1007/s12016-009-8190-6

DO - 10.1007/s12016-009-8190-6

M3 - Article

VL - 40

SP - 27

EP - 41

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1

ER -